Total Payments
$263,903
2024 Payments
$4,686
Companies
7
Transactions
345
Medicare Patients
651
Medicare Billing
$72,074
Payment Breakdown by Category
Other$200,609 (76.0%)
Consulting$26,038 (9.9%)
Travel$23,332 (8.8%)
Food & Beverage$6,892 (2.6%)
Research$6,635 (2.5%)
Education$397.31 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $194,068 | 130 | 73.5% |
| Consulting Fee | $26,038 | 8 | 9.9% |
| Travel and Lodging | $23,332 | 67 | 8.8% |
| Food and Beverage | $6,892 | 123 | 2.6% |
| Unspecified | $6,635 | 9 | 2.5% |
| Honoraria | $6,500 | 1 | 2.5% |
| Education | $397.31 | 6 | 0.2% |
| Grant | $41.50 | 1 | 0.0% |
Payments by Type
General
$257,268
336 transactions
Research
$6,635
9 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan, Inc. | $108,307 | 115 | $0 (2021) |
| Lilly USA, LLC | $89,823 | 158 | $0 (2022) |
| ABBVIE INC. | $36,937 | 35 | $0 (2024) |
| Biohaven Pharmaceuticals, Inc. | $13,047 | 19 | $0 (2021) |
| BioDelivery Sciences International, Inc. | $7,572 | 11 | $0 (2021) |
| Biohaven Pharmaceutical Holding Company Ltd. | $4,394 | 4 | $0 (2022) |
| Eli Lilly and Company | $3,823 | 3 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,686 | 6 | ABBVIE INC. ($4,686) |
| 2023 | $1,800 | 2 | ABBVIE INC. ($1,800) |
| 2022 | $16,454 | 17 | ABBVIE INC. ($12,036) |
| 2021 | $67,074 | 68 | AbbVie Inc. ($18,415) |
| 2020 | $64,886 | 70 | Allergan, Inc. ($47,505) |
| 2019 | $75,123 | 126 | Lilly USA, LLC ($42,977) |
| 2018 | $29,703 | 44 | Lilly USA, LLC ($18,406) |
| 2017 | $4,176 | 12 | Allergan Inc. ($3,088) |
All Payment Transactions
345 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/27/2024 | ABBVIE INC. | BOTOX (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,750.00 | General |
| Category: NEUROSCIENCE | ||||||
| 02/03/2024 | ABBVIE INC. | BOTOX (Biological) | Travel and Lodging | In-kind items and services | $455.40 | General |
| Category: NEUROSCIENCE | ||||||
| 02/03/2024 | ABBVIE INC. | BOTOX (Biological) | Travel and Lodging | In-kind items and services | $326.57 | General |
| Category: NEUROSCIENCE | ||||||
| 02/03/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $69.50 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 02/03/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $59.56 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 02/03/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $24.81 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 10/24/2023 | ABBVIE INC. | BOTOX (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $900.00 | General |
| Category: NEUROSCIENCE | ||||||
| 06/27/2023 | ABBVIE INC. | BOTOX (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $900.00 | General |
| Category: NEUROSCIENCE | ||||||
| 11/18/2022 | Lilly USA, LLC | EMGALITY (Drug) | Food and Beverage | In-kind items and services | $24.37 | General |
| Category: Neuroscience | ||||||
| 06/12/2022 | ABBVIE INC. | BOTOX (Biological) | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| Category: NEUROSCIENCE | ||||||
| 06/12/2022 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | Cash or cash equivalent | $113.15 | General |
| Category: NEUROSCIENCE | ||||||
| 06/12/2022 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | Cash or cash equivalent | $11.68 | General |
| Category: NEUROSCIENCE | ||||||
| 06/11/2022 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $31.14 | General |
| Category: NEUROSCIENCE | ||||||
| 05/10/2022 | ABBVIE INC. | BOTOX (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,000.00 | General |
| Category: NEUROSCIENCE | ||||||
| 04/30/2022 | ABBVIE INC. | BOTOX (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,125.00 | General |
| Category: NEUROSCIENCE | ||||||
| 04/30/2022 | ABBVIE INC. | BOTOX (Biological) | Travel and Lodging | In-kind items and services | $451.20 | General |
| Category: NEUROSCIENCE | ||||||
| 04/30/2022 | ABBVIE INC. | BOTOX (Biological) | Travel and Lodging | In-kind items and services | $292.67 | General |
| Category: NEUROSCIENCE | ||||||
| 04/30/2022 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $47.93 | General |
| Category: NEUROSCIENCE | ||||||
| 04/30/2022 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $38.86 | General |
| Category: NEUROSCIENCE | ||||||
| 04/30/2022 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $23.96 | General |
| Category: NEUROSCIENCE | ||||||
| 02/21/2022 | Biohaven Pharmaceutical Holding Company Ltd. | NURTEC ODT (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,700.00 | General |
| Category: PRIMARY CARE | ||||||
| 02/21/2022 | Biohaven Pharmaceutical Holding Company Ltd. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $21.57 | General |
| Category: PRIMARY CARE | ||||||
| 02/18/2022 | ABBVIE INC. | UBRELVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| Category: NEUROSCIENCE | ||||||
| 02/08/2022 | Biohaven Pharmaceutical Holding Company Ltd. | NURTEC ODT (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,550.00 | General |
| Category: PRIMARY CARE | ||||||
| 02/08/2022 | Biohaven Pharmaceutical Holding Company Ltd. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $122.22 | General |
| Category: PRIMARY CARE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PREVENTIVE TREATMENT OF MIGRAINE: OUTCOMES FOR PATIENTS IN REAL-WORLD HEALTHCARE SYSTEMS (TRIUMPH) | Eli Lilly and Company | $2,735 | 1 |
| A MULTICENTER, RANDOMIZED, OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLOERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRANE WITH R WITHOUT AURA | Allergan Inc. | $1,406 | 3 |
| A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SINGLE ATTACK STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRAINE | Allergan Inc. | $1,406 | 3 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH CHRONIC MIGRAINE - THE REGAIN STUDY | Eli Lilly and Company | $979.20 | 1 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH EPISODIC MIGRAINE - THE EVOLVE-2 STUDY | Eli Lilly and Company | $109.05 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 8 | 264 | 630 | $131,084 | $30,077 |
| 2020 | 13 | 387 | 726 | $153,819 | $41,996 |
Total Patients
651
Total Services
1,356
Medicare Billing
$72,074
Procedure Codes
21
All Medicare Procedures & Services
21 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 64400 | Injection of anesthetic agent and/or steroid into trigeminal nerve of face | Office | 2021 | 39 | 263 | $64,908 | $8,663 | 13.3% |
| 64615 | Injection of chemical for destruction of facial and neck nerve muscles on both sides of face | Office | 2021 | 30 | 63 | $16,184 | $5,688 | 35.1% |
| 64405 | Injection of anesthetic agent and/or steroid into greater occipital nerve of upper neck and back of head | Office | 2021 | 25 | 81 | $19,331 | $4,327 | 22.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 55 | 64 | $10,476 | $4,209 | 40.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 67 | 73 | $7,660 | $3,464 | 45.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 22 | 27 | $3,969 | $1,503 | 37.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 11 | 11 | $4,044 | $1,413 | 34.9% |
| 20553 | Injections of trigger points in 3 or more muscles | Office | 2021 | 15 | 48 | $4,512 | $810.41 | 18.0% |
| 64400 | Injection of anesthetic agent and/or steroid into trigeminal nerve of face | Office | 2020 | 39 | 221 | $54,663 | $8,043 | 14.7% |
| 64615 | Injection of chemical for destruction of facial and neck nerve muscles on both sides of face | Office | 2020 | 33 | 79 | $20,183 | $7,225 | 35.8% |
| 64405 | Injection of anesthetic agent and/or steroid into greater occipital nerve of upper neck and back of head | Office | 2020 | 27 | 77 | $18,714 | $4,589 | 24.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 27 | 27 | $11,016 | $4,450 | 40.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 61 | 69 | $11,331 | $4,002 | 35.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 45 | 57 | $8,379 | $3,370 | 40.2% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 25 | 25 | $6,900 | $2,828 | 41.0% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 18 | 18 | $4,822 | $1,715 | 35.6% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 26 | 26 | $3,806 | $1,465 | 38.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 35 | 38 | $4,196 | $1,414 | 33.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 14 | 14 | $3,136 | $1,227 | 39.1% |
| 20553 | Injections of trigger points in 3 or more muscles | Office | 2020 | 15 | 52 | $4,748 | $925.69 | 19.5% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Office | 2020 | 22 | 23 | $1,925 | $743.39 | 38.6% |
About Dr. Amelito Malapira, M.D
Dr. Amelito Malapira, M.D is a Specialist healthcare provider based in Virginia Beach, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/28/2006. The National Provider Identifier (NPI) number assigned to this provider is 1710914239.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Amelito Malapira, M.D has received a total of $263,903 in payments from pharmaceutical and medical device companies, with $4,686 received in 2024. These payments were reported across 345 transactions from 7 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($194,068).
As a Medicare-enrolled provider, Malapira has provided services to 651 Medicare beneficiaries, totaling 1,356 services with total Medicare billing of $72,074. Data is available for 2 years (2020–2021), covering 21 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Other Specialties Neurology
- Location Virginia Beach, VA
- Active Since 06/28/2006
- Last Updated 11/29/2010
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1710914239
Products in Payments
- UBRELVY (Drug) $68,784
- BOTOX (Biological) $45,429
- EMGALITY (Drug) $40,806
- BOTOX (Drug) $26,981
- NURTEC ODT (Drug) $17,441
- REYVOW (Drug) $13,888
- ELYXYB - CELECOXIB (Drug) $7,572
- BOTOX CHRONIC MIGRAINE (Drug) $115.37
- BOTOX - NEUROLOGY (Drug) $97.32
- BOTOX - NEURO REHAB (Drug) $34.38
- QULIPTA (Drug) $31.14
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Virginia Beach
Dr. David Mcdaniel, M.d., Faad, M.D., FAAD
Specialist — Payments: $296,021
Specialist $296,021
Dr. Michael Cannon, M.d, M.D
Specialist — Payments: $124,073
Specialist $124,073
Dr. Gary Siegel, M.d, M.D
Specialist — Payments: $62,333
Specialist $62,333
Dr. Joanne Lopes, M.d, M.D
Specialist — Payments: $17,701
Specialist $17,701
Dr. Jacqueline Salcedo, M.d, M.D
Specialist — Payments: $14,489
Specialist $14,489
Basil Skenderis, M.d, M.D
Specialist — Payments: $12,650
Specialist $12,650